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ON BEHALF OF THE DREAM INVESTIGATORS
OBJECTIVE — Thiazolidinediones are used to treat type 2 diabetes. Their use has been
associated with peripheral edema and congestive heart failure—outcomes that may have a
genetic etiology.
RESEARCH DESIGN AND METHODS — We genotyped 4,197 participants of the
multiethnic DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medica-
tion) trial with a 50k single nucleotide polymorphisms (SNP) array, which captures 2000
cardiovascular, inﬂammatory, and metabolic genes. We tested 32,088 SNPs for an association
with edema among Europeans who received rosiglitazone (n  965).
RESULTS — OneSNP,rs6123045,inNFATC2wassigniﬁcantlyassociatedwithedema(odds
ratio 1.89 [95% CI 1.47–2.42]; P  5.32  10
7, corrected P  0.017). Homozygous individ-
uals had the highest edema rate (hazard ratio 2.89, P  4.22  10
4) when compared with
individuals homozygous for the protective allele, with heterozygous individuals having an in-
termediate risk. The interaction between the SNP and rosiglitazone for edema was signiﬁcant
(P  7.68  10
3). Six SNPs in NFATC2 were signiﬁcant in both Europeans and Latin Amer-
icans (P  0.05).
CONCLUSIONS — Genetic variation at the NFATC2 locus contributes to edema among
individuals who receive rosiglitazone.
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A
lthoughchangesinlifestylecanpre-
vent or delay diabetes (1), the ma-
jority of patients require multiple
therapeutic strategies to prevent or treat
the disease. Thiazolidinediones (TZDs)
are a class of drugs used in the treatment
of diabetes that derive their insulin sensi-
tizing effects from the activation of the
peroxisome proliferator–activated recep-
tor  (PPAR) (2). TZDs can effectively
control glycemia among diabetic patients
(3).However,theirusehasbeenshownto
causeanincreaseinperipheraledemaand
congestive heart failure (CHF) (4,5).
Edema is the most commonly reported
adverse drug reaction associated with
TZDs, and this has been partly attributed
to the 6–8% increase in plasma volume
thatoccurswiththeiruse(6).Inaddition,
the observed increase in CHF associated
with rosiglitazone may derive from a
shared etiology.
AnaimoftheDiabetesREductionand
Assessment with ramipril and rosiglita-
zone Medication (DREAM) trial was to
determine whether rosiglitazone could
prevent progression to diabetes among
individuals with impaired fasting glucose
(IFG) and/or impaired glucose tolerance
(IGT) (7). Consistent with previous ﬁnd-
ings, a signiﬁcant increase in edema and
CHF among individuals receiving rosigli-
tazone was observed (7). The identiﬁca-
tion of genetic variants that predispose
individuals to edema or CHF could lead
to pretherapeutic screening procedures.
To determine whether genetic variation
contributes to the etiology of TZD-
inducededema,wetestedcommonsingle
nucleotide polymorphisms (SNPs), cap-
turing 2,000 cardiovascular/metabolic
genes in DREAM trial participants receiv-
ing rosiglitazone.
RESEARCH DESIGN AND
METHODS— The DREAM trial has
been described in detail elsewhere (7).
We tested 32,088 SNPs for an association
with TZD-induced peripheral edema in
965 European individuals receiving ros-
iglitazone.Edemawasdeﬁnedasthepres-
ence of pitting edema at both ankles
reported at any clinic visit, and individu-
als that withdrew from treatment due to
edema were included. We used logistic
regression for each SNP adjusted for age,
sex, BMI, and the use of ACE inhibitors
andcalciumchannelblockers(CCBs).In-
dividuals taking diuretics were excluded
from all analyses. The ﬁrst 10 principal
components of the shared alleles (identi-
cal by state) were included as covariates.
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SNP and rosiglitazone, we performed a
logistic regression analysis that included
the main effects of the SNP, rosiglitazone,
and their interaction term. Survival
curves for each genotypic class and the
corresponding hazard ratios (HRs) were
calculated from a Cox proportional haz-
ard analysis. A detailed description of
all materials and methods is available in
in an online appendix available at http://
care.diabetesjournals.org/cgi/content/
full/dc10-0452/DC1.
RESULTS— In our genetic substudy
of DREAM, we observed an increase in
edema among individuals who received
rosiglitazone (n  390 [22.3%]) versus
placebo (n  256 [14.5%]). Among the
Europeans, 253 (26.2%) individuals re-
ceiving rosiglitazone experienced edema
compared with 154 (16.1%) receiving
placebo (P  8.63  10
7) (supplemen-
tary Table 1). The clinical characteristics
of the Europeans were not signiﬁcantly
different between the rosiglitazone and
placebo arms (supplementary Table 2).
We tested 32,088 SNPs against
edema in the Europeans receiving rosigli-
tazone. One SNP, rs6123045, in the
nuclear factor of activated T-cells cyto-
plasmic calcineurin-dependent 2
(NFATC2) gene was signiﬁcantly associ-
ated with edema (odds ratio [OR] 1.89
[95% CI 1.47–2.42]; P  5.32  10
7,
corrected P  0.017) (Fig. 1A). The dis-
tribution of the observed versus the
expectedPvaluesisshowninsupplemen-
tary Fig. 1. We detected a signiﬁcant in-
teraction between rs6123045 and
rosiglitazone treatment for edema in Eu-
ropeans (P  7.68  10
3). The effect of
rs6123045, although in the same direc-
tion, was not signiﬁcantly associated with
edema in the placebo group (OR 1.16,
P  0.29) (Fig. 1B).
A Cox proportional hazards analysis
revealed that individuals homozygous for
theriskallelehadadecreaseinthetimeto
the ﬁrst report of edema in comparison
with individuals heterozygous or ho-
mozygous for the protective allele (HR
1.76, P  3.43  10
5 and HR 2.89, P 
4.22  10
4, respectively) (Fig. 1B). The
effect appears to be additive because het-
erozygous individuals had an increased
rate of edema compared with homozy-
gous individuals (HR 1.64, P  0.11).
AmongEuropeansreceivingrosiglita-
zone, rs6123045 was not signiﬁcantly as-
sociated with diabetes or death or with
Figure1—A:ResultsoftheassociationanalysisbetweenSNPsandTZD-inducedperipheraledemaat
theNFATC2locus.ThelogofthePvaluesareplottedagainstSNPlocation.Pvalueswerecalculated
fromalogisticregressionanalysisadjustedforage,sex,BMI,anduseoframiprilandCCBs,aswellas
the ﬁrst 10 principal components of the alleles shared identity by state among the European and Latin
American individuals. Individuals taking diuretics were excluded from the analysis. The dashed lines
indicate Bonferroni corrected and nominal signiﬁcance. Inset: Results of the initial association scan of
32,088SNPsandTZD-inducedperipheraledemainEuropeans(n965)receivingrosiglitazone.The
log of the P values are plotted against SNP location for each chromosome. B: Survival curves esti-
mated from the Cox proportional hazards model of time to the ﬁrst occurrence of edema according to
thers6123045genotype.Europeanindividualshomozygousfortheriskallele(CC)haveanincreasein
the rate to the ﬁrst report of edema in comparison with the individuals heterozygous (CT) or homozy-
gous (TT) for the protective allele (adjusted HR 1.76, P  3.43  10
5 and adjusted HR 2.89, P 
4.22  10
4, respectively). Inset: The effect of the rs6123045 SNP on peripheral edema among
European individuals receiving rosiglitazone or placebo. 33.6% (158 of 470) of individuals homozy-
gous for the risk allele, 20.8% (84 of 403) of heterozygous individuals, and 12.9% (12 of 93) of
individuals homozygous for the protective allele developed edema while receiving rosiglitazone com-
pared with 18.0% (85 of 473), 13.8% (56 of 404), and 16.5% (13 of 79), respectively, while receiving
placebo. The per-allele OR and 95% CI of the logistic regression analysis are shown.
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CHF, myocardial infarction, stroke, an-
gina, or a composite of these outcomes
(data not shown).
rs6123045wasnotsigniﬁcantlyasso-
ciated with TZD-induced edema in Latin
Americans. However, six SNPs in
NFATC2 were signiﬁcant in both Europe-
ansandLatinAmericans(Fig.1A).Ahap-
lotypedeﬁnedbytheseSNPsissigniﬁcant
in both populations (OR 0.45 [95% CI
0.30–0.66]; P  2.26  10
5 and OR
0.34 [95% CI 0.13–0.90]; P  1.47 
10
2 in Europeans and Latin Americans,
respectively) (data not shown). All signif-
icantly associated SNPs were in Hardy-
Weinberg equilibrium (P  0.05).
CONCLUSIONS — We demonstrated
thatvariationwithinNFATC2contributes
to TZD-induced edema. rs6123045 was
signiﬁcantly associated with TZD-
induced edema among Europeans when
corrected for multiple testing. The signif-
icant interaction between rs6123045 and
rosiglitazone treatment for edema (P 
7.68  10
3) among the European
DREAM participants highlights its contri-
bution to the etiology of TZD-induced
edema. rs6123045 was not signiﬁcantly
associated with TZD-induced edema in
Latin Americans. However, six SNPs in
the same region are associated with TZD-
induced edema and deﬁne a signiﬁcantly
associatedhaplotypeinbothpopulations.
Previous studies of either TZD-
induced or dual PPAR agonist–induced
edema (8–11) were smaller in size (n 
730) and tested fewer genes ( 222).
None of these studies analyzed the
NFATC2 gene. Of the 38 SNPs previously
associated with edema, 20 are captured
by the ITMAT-Broad-CARE (IBC) array
used in our study, and we were thus able
to directly test them. However, we were
unable to replicate any of these associa-
tions in Europeans (P  0.05).
The NFATC2 gene encodes a cyto-
plasmic component of the NFAT
transcription complex. Four NFAT cyto-
plasmic component proteins (NFATc1-
c4) are known, and these are translocated
to the nucleus after being dephosphory-
latedbythephosphatasecalcineurin(12).
Treatmentofcardiomyocyteswithrosigli-
tazone inhibited endothelin-1 induced
calcineurin activity, suppressed the nu-
clear translocation of NFATc4, and en-
hanced the association of PPAR with
calcineurin/NFATc4 (13). The constitu-
tive activation of either calcineurin or
NFATc4 in mice leads to cardiac hyper-
trophy and heart failure (14). In addition,
Nfatc2 null mice are protected from cal-
cineurin-induced cardiac hypertrophy
(15). In the context of these ﬁndings, our
results are provocative and constitute a
steptowardelucidatingtheetiologyofthe
CHF associated with TZD use (5).
Identifying the speciﬁc genetic vari-
ants interacting with TZDs and resulting
in edema or cardiovascular events may
haveimportantclinicalconsequencesand
enablegeneticvariantdirecteduseofTZD
drugs among people with dysglycemia.
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